文献速递青光眼

妊娠期使用降眼压药物与新生儿不良结局风险

Intraocular pressure-lowering medications during pregnancy and risk of neonatal adverse outcomes: a propensity score analysis using a large database.
PubMed 文献 · Br J Ophthalmol · 2020-09-09

该回顾性队列研究利用日本JMDC理赔数据库(2005-2018年),纳入826例青光眼孕妇,其中91例(11%)在妊娠早期使用降眼压药物。经倾向评分调整后,使用降眼压药物与先天畸形、早产、低出生体重及三者复合结局均无显著关联。

要点

  • 妊娠早期使用降眼压药物未显著增加先天畸形、早产或低出生体重风险。
  • 仅用前列腺素类似物或仅用β受体阻滞剂的结果与总体结果相似。
  • 该研究为回顾性数据库分析,样本量有限,需谨慎解读。

核心结论

  • 妊娠早期使用降眼压药物与先天畸形、早产及低出生体重的增加无显著关联。

研究设计与样本

  • 回顾性队列研究,使用日本JMDC理赔数据库(2005-2018年),纳入826例青光眼孕妇。

主要发现

  • 使用降眼压药物者先天畸形发生率为9.9%,未使用者为6.4%。
  • 使用降眼压药物者早产发生率为2.2%,未使用者为4.5%。
  • 使用降眼压药物者低出生体重发生率为9.9%,未使用者为6.0%。
  • 使用降眼压药物者复合结局发生率为17.6%,未使用者为13.3%。
  • 倾向评分调整后,降眼压药物与先天畸形(aOR 1.43;95%CI 0.66-3.12)、早产(aOR 0.45;95%CI 0.10-1.97)、低出生体重(aOR 2.11;95%CI 0.98-4.57)及复合结局(aOR 1.40;95%CI 0.78-2.53)均无显著关联。

临床怎么用

  • 对于妊娠期青光眼患者,使用降眼压药物未显示显著增加新生儿不良结局风险,可为临床决策提供参考。

局限性

  • 本研究为回顾性数据库分析,可能存在未测量的混杂因素。
  • 样本量有限,仅826例孕妇,其中91例使用降眼压药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To investigate the association between exposure to intraocular pressure (IOP)-lowering medications during pregnancy and neonatal adverse outcomes. METHODS: This retrospective, cohort study used the JMDC Claims Database (JMDC, Tokyo, Japan), 2005-2018. We extracted data on pregnant women with glaucoma, including dispensation of (1) any IOP-lowering medications, (2) only prostaglandin analogues (PGs) and 3) only beta-blockers, during the first trimester. We compared frequency of congenital anomalies (CA), preterm birth (PB), low birth weight (LBW) and the composite outcome of these three measures, between the women with and without IOP-lowering medications. We calculated propensity scores (PSs) using logistic regression in which use of IOP-lowering medications was regressed against known confounders (disorders during pregnancy and other chronic comorbidities). We then conducted logistic regression in which neonatal adverse outcomes were regressed against use of IOP-lowering medications with adjustment for the PS. RESULTS: We identified 826 eligible women, 91 (11%) of whom had received any IOP-lowering medications. CA occurred in 9.9% and 6.4%, PB in 2.2% and 4.5%, LBW in 9.9% and 6.0% and composite outcome in 17.6% and 13.3% of mothers with and without IOP-lowering medications, respectively. After adjustment for PS, IOP-lowering medications were not significantly associated with more frequent CA (adjusted OR (aOR), 1.43; 95% CI, 0.66 to 3.12), PB (aOR, 0.45; 95% CI, 0.10 to 1.97), LBW (aOR, 2.11; 95% CI, 0.98 to 4.57) or composite outcome (aOR, 1.40; 95% CI, 0.78 to 2.53). Results were similar regarding PGs only and beta-blockers only. CONCLUSIONS: IOP-lowering medications during the first trimester were not significantly associated with increase in CA, PB or LBW.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hashimoto Y, Michihata N, Yamana H, et al. Intraocular pressure-lowering medications during pregnancy and risk of neonatal adverse outcomes: a propensity score analysis using a large database. Br J Ophthalmol. 2020. PMID: 32907812. doi:10.1136/bjophthalmol-2020-316198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。